CoChat
Sign Up
Cited by 78

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Preclinical Demonstration of Lentiviral Vector-mediated Correction of Immunological and Metabolic Abnormalities in Models of Adenosine Deaminase Deficiency

Carbonaro, Denise A, Zhang, Lin, Jin, Xiangyang, Montiel-Equihua, Claudia, Geiger, Sabine, Carmo, Marlene, Cooper, Aaron, Fairbanks, Lynette, Kaufman, Michael L, Sebire, Neil J, Hollis, Roger P, Blundell, Michael P, Senadheera, Shantha, Fu, Pei-Yu, Sahaghian, Arineh, Chan, Rebecca Y, Wang, Xiaoyan, Cornetta, Kenneth, Thrasher, Adrian J, Kohn, Donald B, Gaspar, H Bobby·2014·Molecular Therapy
DOI 10.1038/mt.2013.265
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/mt.2013.265

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 46

  1. Hershfield, 1998, Adenosine deaminase deficiency: clinical expression, molecular basis, and therapy, Semin Hematol, 35, 291
  2. Apasov, 2001, Adenosine deaminase deficiency increases thymic apoptosis and causes defective T cell receptor signaling, J Clin Invest, 108, 131, 10.1172/JCI200110360 · DOI
  3. Albuquerque, 2004, Bilateral sensorineural deafness in adenosine deaminase-deficient severe combined immunodeficiency, J Pediatr, 144, 278, 10.1016/j.jpeds.2003.10.055 · DOI
  4. Ratech, 1985, Pathologic findings in adenosine deaminase-deficient severe combined immunodeficiency. I. Kidney, adrenal, and chondro-osseous tissue alterations, Am J Pathol, 120, 157
  5. Blackburn, 1998, Adenosine deaminase-deficient mice generated using a two-stage genetic engineering strategy exhibit a combined immunodeficiency, J Biol Chem, 273, 5093, 10.1074/jbc.273.9.5093 · DOI
  6. Booth, 2007, Management options for adenosine deaminase deficiency; proceedings of the EBMT satellite workshop (Hamburg, March 2006), Clin Immunol, 123, 139, 10.1016/j.clim.2006.12.009 · DOI
  7. Gaspar, 2009, How I treat ADA deficiency, Blood, 114, 3524, 10.1182/blood-2009-06-189209 · DOI
  8. Blaese, 1995, T lymphocyte-directed gene therapy for ADA- SCID: initial trial results after 4 years, Science, 270, 475, 10.1126/science.270.5235.475 · DOI
  9. Aiuti, 2002, Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning, Science, 296, 2410, 10.1126/science.1070104 · DOI · Paper page
  10. Aiuti, 2002, Immune reconstitution in ADA-SCID after PBL gene therapy and discontinuation of enzyme replacement, Nat Med, 8, 423, 10.1038/nm0502-423 · DOI
  11. Aiuti, 2009, Gene therapy for immunodeficiency due to adenosine deaminase deficiency, N Engl J Med, 360, 447, 10.1056/NEJMoa0805817 · DOI
  12. Candotti, 2012, Gene therapy for adenosine deaminase-deficient severe combined immune deficiency: clinical comparison of retroviral vectors and treatment plans, Blood, 120, 3635, 10.1182/blood-2012-02-400937 · DOI
  13. Gaspar, 2011, Hematopoietic stem cell gene therapy for adenosine deaminase-deficient severe combined immunodeficiency leads to long-term immunological recovery and metabolic correction, Sci Transl Med, 3, 97ra80, 10.1126/scitranslmed.3002716 · DOI
  14. Boztug, 2010, Stem-cell gene therapy for the Wiskott-Aldrich syndrome, N Engl J Med, 363, 1918, 10.1056/NEJMoa1003548 · DOI · Paper page
  15. Hacein-Bey-Abina, 2003, LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1, Science, 302, 415, 10.1126/science.1088547 · DOI · Paper page
  16. Howe, 2008, Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients, J Clin Invest, 118, 3143, 10.1172/JCI35798 · DOI · Paper page
  17. Ott, 2006, Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1, Nat Med, 12, 401, 10.1038/nm1393 · DOI · Paper page
  18. Stein, 2010, Genomic instability and myelodysplasia with monosomy 7 consequent to EVI1 activation after gene therapy for chronic granulomatous disease, Nat Med, 16, 198, 10.1038/nm.2088 · DOI · Paper page
  19. Aiuti, 2007, Multilineage hematopoietic reconstitution without clonal selection in ADA-SCID patients treated with stem cell gene therapy, J Clin Invest, 117, 2233, 10.1172/JCI31666 · DOI
  20. Dull, 1998, A third-generation lentivirus vector with a conditional packaging system, J Virol, 72, 8463, 10.1128/JVI.72.11.8463-8471.1998 · DOI · Paper page
  21. Miyoshi, 1998, Development of a self-inactivating lentivirus vector, J Virol, 72, 8150, 10.1128/JVI.72.10.8150-8157.1998 · DOI · Paper page
  22. Modlich, 2009, Insertional transformation of hematopoietic cells by self-inactivating lentiviral and gammaretroviral vectors, Mol Ther, 17, 1919, 10.1038/mt.2009.179 · DOI · Paper page
  23. Modlich, 2006, Cell-culture assays reveal the importance of retroviral vector design for insertional genotoxicity, Blood, 108, 2545, 10.1182/blood-2005-08-024976 · DOI · Paper page
  24. Cartier, 2010, Gene therapy of x-linked adrenoleukodystrophy using hematopoietic stem cells and a lentiviral vector, Bull Acad Natl Med, 194, 255
  25. Montiel-Equihua, 2012, The beta-globin locus control region in combination with the EF1alpha short promoter allows enhanced lentiviral vector-mediated erythroid gene expression with conserved multilineage activity, Mol Ther, 20, 1400, 10.1038/mt.2012.50 · DOI
  26. Corrigan-Curay, 2012, Challenges in vector and trial design using retroviral vectors for long-term gene correction in hematopoietic stem cell gene therapy, Mol Ther, 20, 1084, 10.1038/mt.2012.93 · DOI
  27. Carbonaro, 2012, Gene therapy/bone marrow transplantation in ADA-deficient mice: roles of enzyme-replacement therapy and cytoreduction, Blood, 120, 3677, 10.1182/blood-2012-02-408591 · DOI
  28. Thompson, 2000, Metabolites from apoptotic thymocytes inhibit thymopoiesis in adenosine deaminase-deficient fetal thymic organ cultures, J Clin Invest, 106, 1149, 10.1172/JCI9944 · DOI
  29. Zhang, 2010, A ubiquitous chromatin opening element (UCOE) confers resistance to DNA methylation-mediated silencing of lentiviral vectors, Mol Ther, 18, 1640, 10.1038/mt.2010.132 · DOI
  30. Mortellaro, 2006, Ex vivo gene therapy with lentiviral vectors rescues adenosine deaminase (ADA)-deficient mice and corrects their immune and metabolic defects, Blood, 108, 2979, 10.1182/blood-2006-05-023507 · DOI
  31. Booth, 2012, Non-infectious lung disease in patients with adenosine deaminase deficient severe combined immunodeficiency, J Clin Immunol, 32, 449, 10.1007/s10875-012-9658-3 · DOI
  32. Ficara, 2004, IL-3 or IL-7 increases ex vivo gene transfer efficiency in ADA-SCID BM CD34+ cells while maintaining in vivo lymphoid potential, Mol Ther, 10, 1096, 10.1016/j.ymthe.2004.08.014 · DOI
  33. Uchida, 2011, Optimal conditions for lentiviral transduction of engrafting human CD34+ cells, Gene Ther, 18, 1078, 10.1038/gt.2011.63 · DOI
  34. Kohn, 2012, Lymphoid priming in human bone marrow begins before expression of CD10 with upregulation of L-selectin, Nat Immunol, 13, 963, 10.1038/ni.2405 · DOI
  35. Beard, 2007, Comparison of HIV-derived lentiviral and MLV-based gammaretroviral vector integration sites in primate repopulating cells, Mol Ther, 15, 1356, 10.1038/sj.mt.6300159 · DOI
  36. Beard, 2007, Unique integration profiles in a canine model of long-term repopulating cells transduced with gammaretrovirus, lentivirus, or foamy virus, Hum Gene Ther, 18, 423, 10.1089/hum.2007.011 · DOI
  37. Aiuti, 2013, The committee for advanced therapies’ of the European Medicines Agency reflection paper on management of clinical risks deriving from insertional mutagenesis, Hum Gene Ther Clin Dev, 24, 47, 10.1089/humc.2013.119 · DOI
  38. Biffi, 2013, Lentiviral hematopoietic stem cell gene therapy benefits metachromatic leukodystrophy, Science, 341, 1233158, 10.1126/science.1233158 · DOI · Paper page
  39. Shultz, 2005, Human lymphoid and myeloid cell development in NOD/LtSz-scid IL2R gamma null mice engrafted with mobilized human hemopoietic stem cells, J Immunol, 174, 6477, 10.4049/jimmunol.174.10.6477 · DOI
  40. Gaspar, 2006, Successful reconstitution of immunity in ADA-SCID by stem cell gene therapy following cessation of PEG-ADA and use of mild preconditioning, Mol Ther, 14, 505, 10.1016/j.ymthe.2006.06.007 · DOI
  41. Demaison, 2002, High-level transduction and gene expression in hematopoietic repopulating cells using a human immunodeficiency [correction of imunodeficiency] virus type 1-based lentiviral vector containing an internal spleen focus forming virus promoter, Hum Gene Ther, 13, 803, 10.1089/10430340252898984 · DOI
  42. Schambach, 2000, Context dependence of different modules for posttranscriptional enhancement of gene expression from retroviral vectors, Mol Ther, 2, 435, 10.1006/mthe.2000.0191 · DOI
  43. Cooper, 2011, Highly efficient large-scale lentiviral vector concentration by tandem tangential flow filtration, J Virol Methods, 177, 1, 10.1016/j.jviromet.2011.06.019 · DOI
  44. Leath, 2012, Developing novel lentiviral vectors into clinical products, Meth Enzymol, 507, 89, 10.1016/B978-0-12-386509-0.00005-3 · DOI
  45. Nightingale, 2006, Transient gene expression by nonintegrating lentiviral vectors, Mol Ther, 13, 1121, 10.1016/j.ymthe.2006.01.008 · DOI · Paper page
  46. Tukey, 1957, Variances of variance components: II. Unbalanced single classifications, The Annals of Mathematical Statistics, 28, 43, 10.1214/aoms/1177707036 · DOI

Cited by

See all 78

Metadata

Authors
Carbonaro, D. A., Zhang, L., Jin, X., Montiel-Equihua, C., Geiger, S., Carmo, M., Cooper, A., Fairbanks, L., Kaufman, M. L., Sebire, N. J., Hollis, R. P., Blundell, M. P., Senadheera, S., Fu, P.-Y., Sahaghian, A., Chan, R. Y., Wang, X., Cornetta, K., Thrasher, A. J., Kohn, D. B., & Gaspar, H. B.
Venue
Molecular Therapy
Publisher
Elsevier BV
Published
2014-03
Volume
22
Issue
3
Pages
607-622
ISSN
1525-0016
DOI
10.1038/mt.2013.265
Cited by
78
References
6
Language
en
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review